339 related articles for article (PubMed ID: 25381816)
1. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
[TBL] [Abstract][Full Text] [Related]
2. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
[TBL] [Abstract][Full Text] [Related]
3. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.
Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO
J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640
[TBL] [Abstract][Full Text] [Related]
4. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
[TBL] [Abstract][Full Text] [Related]
5. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
[TBL] [Abstract][Full Text] [Related]
7. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.
Rennel E; Waine E; Guan H; Schüler Y; Leenders W; Woolard J; Sugiono M; Gillatt D; Kleinerman E; Bates D; Harper S
Br J Cancer; 2008 Apr; 98(7):1250-7. PubMed ID: 18349828
[TBL] [Abstract][Full Text] [Related]
8. WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.
Belali T; Wodi C; Clark B; Cheung MK; Craig TJ; Wheway G; Wagner N; Wagner KD; Roberts S; Porazinski S; Ladomery M
Biochim Biophys Acta Gene Regul Mech; 2020 Dec; 1863(12):194642. PubMed ID: 33017668
[TBL] [Abstract][Full Text] [Related]
9. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
[TBL] [Abstract][Full Text] [Related]
10. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
Oltean S; Gammons M; Hulse R; Hamdollah-Zadeh M; Mavrou A; Donaldson L; Salmon AH; Harper SJ; Ladomery MR; Bates DO
Biochem Soc Trans; 2012 Aug; 40(4):831-5. PubMed ID: 22817743
[TBL] [Abstract][Full Text] [Related]
11. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.
Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO
J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117
[TBL] [Abstract][Full Text] [Related]
12. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.
Gammons MV; Fedorov O; Ivison D; Du C; Clark T; Hopkins C; Hagiwara M; Dick AD; Cox R; Harper SJ; Hancox JC; Knapp S; Bates DO
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6052-62. PubMed ID: 23887803
[TBL] [Abstract][Full Text] [Related]
13. VEGF
Boudria A; Abou Faycal C; Jia T; Gout S; Keramidas M; Didier C; Lemaître N; Manet S; Coll JL; Toffart AC; Moro-Sibilot D; Albiges-Rizo C; Josserand V; Faurobert E; Brambilla C; Brambilla E; Gazzeri S; Eymin B
Oncogene; 2019 Feb; 38(7):1050-1066. PubMed ID: 30194450
[TBL] [Abstract][Full Text] [Related]
14. Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion.
Bullock N; Potts J; Simpkin AJ; Koupparis A; Harper SJ; Oxley J; Oltean S
J Clin Pathol; 2016 Feb; 69(2):171-5. PubMed ID: 26500332
[TBL] [Abstract][Full Text] [Related]
15. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
[TBL] [Abstract][Full Text] [Related]
16. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
[TBL] [Abstract][Full Text] [Related]
17. SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing.
Mavrou A; Oltean S
Pharmacol Res; 2016 May; 107():276-281. PubMed ID: 26995304
[TBL] [Abstract][Full Text] [Related]
18. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
Peiris-Pagès M; Harper SJ; Bates DO; Ramani P
J Pathol; 2010 Oct; 222(2):138-47. PubMed ID: 20662003
[TBL] [Abstract][Full Text] [Related]
19. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy.
Malhi NK; Allen CL; Stewart E; Horton KL; Riu F; Batson J; Amoaku W; Morris JC; Arkill KP; Bates DO
Am J Physiol Heart Circ Physiol; 2022 Jun; 322(6):H1014-H1027. PubMed ID: 35302878
[TBL] [Abstract][Full Text] [Related]
20. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]